Compare Cassava Sciences Inc (FLNA) vs Advanced Drainage Systems Inc (WMS) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

Advanced Drainage Systems (WMS) trades at $126.36, up 0.22% with a bearish technical signal despite strong fundamental performance. The company reported Q2 2026 EPS of $2.49, beating estimates by 18.6%, continuing a trend of earnings outperformance. Key financial metrics show robust profitability with 14% net income margin and 24.9% ROE, though cash flow turned negative in 2025 due to increased capital investments. Recent news highlights sustainability initiatives and institutional positioning changes.

WMS presents a compelling investment case with consistent earnings beats and strong analyst support ($188.70 price target), but faces near-term technical headwinds and cash flow pressures from aggressive expansion. The stock's current valuation at 21.5x P/E appears reasonable given growth prospects, though investors should monitor execution of NDS integration and capital allocation strategy.